Vol 7, No 2 (2011)
Review paper
Published online: 2011-06-22

open access

Page views 970
Article views/downloads 6392
Get Citation

Connect on Social Media

Connect on Social Media

Maintenance treatment of patients with follicular lymphoma

Piotr Smolewski, Tadeusz Robak
Onkol. Prak. Klin 2011;7(2):84-88.

Abstract

Follicular lymphoma (FL) is a relatively frequent malignant disease, comprising approximately 20% of lymphoid malignancies. Clinically it is defined as an indolent disease. Despite the recent progress in treatment of hematological tumors, FL still remains an incurable disease. In patients with progressive disease, a standard of first line treatment are COP (cyclophosphamide, vincristine, prednizon) or CHOP (cyclophosphamide, doksorubicine, vincristine, prednizon) regimens, administrated in combination with anti-CD20 antigen antibody, rituximab (RIT). Most recently, the role of RIT maintenance in prolongation of disease progression free survival and, potentially, overall survival of FL patients has been underlined.
Onkol. Prak. Klin. 2011; 7, 2: 84–88

Article available in PDF format

View PDF (Polish) Download PDF file